KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Invested Capital (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Invested Capital for 16 consecutive years, with $2.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 17.21% to $2.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 17.21% increase, with the full-year FY2025 number at $2.2 billion, up 17.21% from a year prior.
  • Invested Capital was $2.2 billion for Q4 2025 at Halozyme Therapeutics, up from $2.0 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $2.2 billion in Q4 2025 to a low of $177.8 million in Q1 2024.
  • A 5-year average of $1.4 billion and a median of $1.6 billion in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 88.6% in 2024, then surged 1019.03% in 2025.
  • Halozyme Therapeutics' Invested Capital stood at $984.2 million in 2021, then surged by 70.28% to $1.7 billion in 2022, then decreased by 5.54% to $1.6 billion in 2023, then grew by 18.1% to $1.9 billion in 2024, then grew by 17.21% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for HALO's Invested Capital are $2.2 billion (Q4 2025), $2.0 billion (Q3 2025), and $342.6 million (Q2 2025).